XCUR
Exicure, Inc.6.06
+0.33+5.76%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
38.63MP/E (TTM)
-Basic EPS (TTM)
-3.72Dividend Yield
0%Recent Filings
8-K
Exicure appoints new CEO, interim CFO
Exicure replaced CEO Andy Yoo and CFO Seung Ik Baik—resignations effective February 9, 2026—with Jung Soo Kim as CEO/President and Gyuyeob Lee as Interim CFO/Secretary, both starting February 11. Kim brings 20+ years in strategy, capital markets, and restructuring from roles at AGEDB Technology and Sandcraft. Services flow through Innocircle Advisors. Leadership shakeup signals pivot.
8-K
Board and exec shakeup
Exicure overhauled its board and leadership on February 6, 2026, effective February 9: directors Andy Yoo, Seung Ik Baik, and Aejin Hwang resigned without disagreements; Jung Kyu Ham, Jung Soo Kim, and Gyeung Seog Cheon joined with $20,000 annual retainers. CEO Yoo and CFO Baik also resigned, positions vacant, Baik got $150,000 separation pay; remaining directors received $20,000 bonuses. Leadership reset complete.
8-K
Exicure achieves Phase 2 milestone
Exicure hit Milestone 1 on January 16, 2026, under its License and Collaboration Agreement with GPCR Therapeutics by submitting its Phase 2 trial report for stem cell mobilizer Burixafor (NCT05551751) to the FDA. This triggers a $1M payment within 30 days. Progress advances the CXCR4 inhibitor program. Sublicensing income-sharing activates.
8-K
Redeems subsidiary bonds early
8-K
Annual meeting votes passed
Exicure stockholders at the November 6, 2025 Annual Meeting elected Sangjin Yeo and Aejin Hwang as Class II directors until 2028, with 3.5M votes for each versus minimal withheld. They ratified CBIZ CPAs P.C. as auditors for 2025 (3.75M for) and advisory approved executive pay (3.48M for). Routine governance upheld.
CPMV
Mosaic ImmunoEngineering Inc.
0.40+0.00
CURX
Curanex Pharmaceuticals Inc
0.41-0.02
EPIX
ESSA Pharma Inc.
0.20+0.00
EXOZ
eXoZymes Inc.
12.52-1.78
NBY
NovaBay Pharmaceuticals, Inc.
3.16+0.45
OKUR
OnKure Therapeutics, Inc.
3.02-0.18
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
TTNP
Titan Pharmaceuticals, Inc.
4.61-0.18
XBIT
XBiotech Inc.
2.45-0.08
YDES
YD Bio Limited
12.62+0.22